Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy.
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122884484/en/
Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas.
Key Highlights:
- Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, reflecting a global focus on advancing these therapies.
- Pipeline Insights: Solid tumors dominate OVT research, with trials targeting cancers such as melanoma, glioblastoma, and pancreatic cancer.
- Innovative Delivery Systems: Advances like nanoparticle systems and cell-based carriers address key challenges in targeting and delivery.
- Combination Therapies: Integration with immune checkpoint inhibitors, CAR-T therapies, and chemotherapy is enhancing the efficacy and scope of OVT.
- Regulatory Overview: Provides guidance on navigating complex global regulatory pathways, including insights into fast-tracking approvals.
This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122884484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UK CfD AR7 Results Signal New Realities for Offshore Wind Economics Ahead of AR8 — Aegir Insights15.1.2026 10:38:00 CET | Press release
The UK government yesterday published the results of the highly anticipated Contracts for Difference (CfD) Allocation Round 7 (AR7), highlighting both sustained appetite for UK offshore wind and the growing complexity of delivering competitive, bankable bids. The allocation round awarded a record 8.4 GW of offshore wind capacity across eight projects after the government increased the budget during the process. Almost all capacity (8.2 GW) was allocated to fixed-bottom offshore wind, enabling six large-scale projects to move forward and strengthening the UK’s deployment pipeline towards 2030. However, the outcome also revealed a large degree of project concentration, with partial or full ownership of five of the six awarded fixed-bottom projects held by a single developer. In a sector still recovering from cost and delivery risk, AR7 represents a positive outcome and signals an industry beginning to recalibrate under the right support framework. “The AR7 results provide important signa
OPEX® Corporation Presented with Multiple DM Awards by Document Manager Magazine15.1.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has been recognized by Document Manager magazine with multiple DM Awards. At the 2025 awards ceremony held recently in London, OPEX was named the winner in two categories―Imaging Product of the Year: High Volume and Hardware Product of the Year―for its Falcon+® document imaging solution. OPEX also received runners-up accolades, in partnership with Iron Mountain, in the category of Project of the Year: Public Sector, for their NHS Medical Scanning project. “OPEX is honored to receive such prestigious recognition from Document Manager magazine,” said Alban Collas, Director of EMEA Operations, OPEX. “Our team is committed to developing solutions that enable clients to transform how business is conducted. For our imaging solutions to be recognized in this way means so much to us. We’re especially pleased that the DM Awards honored our partnership with
NTT DATA Recognized as a Global Top Employer for Third Consecutive Year15.1.2026 09:00:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announces it has been certified as a Global Top Employer for 2026 by the Top Employers Institute. Recognized for the third year in a row, this prestigious honor places NTT DATA among a select group of just 17 organizations worldwide honored for consistently delivering a high-performing people strategy across its global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115418660/en/ NTT DATA recognized as a Global Top Employer In addition to its global recognition, NTT DATA has also earned four Top Employer 2026 regional seals and 37 country and region seals across North America, Latin America, Asia Pacific, Europe and Africa. The Global Certification is the highest level of recognition offered by the Top Employers Institute and underscores NTT DATA’s ability to align its leadership, leverage data-driven insights and apply validated b
SAP and Syngenta Announce Partnership to Scale AI-Assisted Agriculture15.1.2026 09:00:00 CET | Press release
SAP SE (NYSE: SAP) and Syngenta, a global leader in agricultural innovation, today announced a multi-year strategic technology partnership to accelerate AI-assisted innovation across Syngenta’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115682130/en/ Jeff Rowe - CEO of Syngenta Group (left) and Christian Klein - CEO of SAP (right) The partnership will embed artificial intelligence at the core of Syngenta’s enterprise, modernizing operations and enabling accelerated innovation through advanced data analytics across the business — from manufacturing and supply chain to grower-facing products and services. Agriculture continues to navigate challenges driven by climate variability, supply chain complexity, and global uncertainty. By deploying AI-assisted tools enterprise-wide, this partnership positions Syngenta to meet the challenge of feeding a projected 10 billion people by 2050, while unlocking fast
Advanced Sterilization Products (ASP) Announces CE Mark for ULTRA GI™ Cycle for Duodenoscopes in Partnership with FUJIFILM Healthcare Europe15.1.2026 09:00:00 CET | Press release
New cycle for the STERRAD™ 100NX Sterilizer introduces a validated sterilization method for complex endoscopes, promoting patient safety through innovation. ASP International GmbH (“ASP”), a division of Fortive (NYSE: FTV), in collaboration with FUJIFILM Healthcare Europe GmbH, proudly announces that the ULTRA GI™ Cycle has received CE mark approval. The ULTRA GI™ Cycle is the latest innovation for the STERRAD™ 100NX Sterilizer with ALLClear™ Technology. The ULTRA GI™ Cycle’s receipt of the CE mark represents a pivotal advancement in elevating patient safety across healthcare facilities and addressing the complex challenges associated with traditional reprocessing methods. “This is a meaningful step forward in our mission to make duodenoscope reprocessing safer across Europe,” said Chad Rohrer, President, ASP. “By bringing hydrogen peroxide gas plasma sterilization into routine practice, we’re giving clinicians greater confidence to focus on what matters most – their patients.” ASP’s i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom